LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Ocular Therapeutix Inc

Closed

SectorHealthcare

12.74 0.08

Overview

Share price change

24h

Current

Min

12.55

Max

12.92

Key metrics

By Trading Economics

Income

-3.8M

-68M

Sales

2.8M

13M

Profit margin

-503.856

Employees

274

EBITDA

146K

-64M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+36.74% upside

Dividends

By Dow Jones

Next Earnings

13 Nov 2025

Market Stats

By TradingEconomics

Market Cap

244M

2.2B

Previous open

12.66

Previous close

12.74

News Sentiment

By Acuity

30%

70%

87 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Ocular Therapeutix Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Sept 2025, 23:37 UTC

Hot Stocks

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 Sept 2025, 20:41 UTC

Earnings

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 Sept 2025, 20:30 UTC

Earnings

GameStop 2Q Sales, Profit Rise

9 Sept 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 Sept 2025, 21:35 UTC

Earnings

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 21:32 UTC

Earnings

Oracle's Backlog Swells With Big Customer Deals -- Update

9 Sept 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Sept 2025, 20:33 UTC

Earnings

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 Sept 2025, 20:26 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:23 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:12 UTC

Earnings

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 Sept 2025, 20:07 UTC

Earnings

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Software Revenue $5.72B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Synopsys 3Q Adj EPS $3.39 >SNPS

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Rev $14.93B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q EPS $1.01 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Synopsys 3Q EPS $1.50 >SNPS

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Services Revenue $1.35B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Adj EPS $1.47 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Hardware Revenue $670M >ORCL

Peer Comparison

Price change

Ocular Therapeutix Inc Forecast

Price Target

By TipRanks

36.74% upside

12 Months Forecast

Average 17.38 USD  36.74%

High 21 USD

Low 14 USD

Based on 9 Wall Street analysts offering 12 month price targets forOcular Therapeutix Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

6.97 / 7.62Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

87 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat